2025 Q3 -tulosraportti
99 päivää sitten
‧35 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
39 972
Myynti
Määrä
41 466
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 598 | - | - | ||
| 961 | - | - | ||
| 381 | - | - | ||
| 102 | - | - | ||
| 619 | - | - |
Ylin
2,845VWAP
Alin
2,7VaihtoMäärä
2,9 1 064 968
VWAP
Ylin
2,845Alin
2,7VaihtoMäärä
2,9 1 064 968
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 19.2. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 7.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 päivää sittenThen surely all negative things should be priced in and clear by now and the price will probably land just under 2 at the report and then some talk and decision about an emission and then it's down to 1kr before the end of February. Like.
·6.2.Full-year sales for 2025 will amount to 71.2 MSEK, an increase of 125 percent compared to 2024. Are people reading the report or?6.2.6.2.Redeye 16.01: The main reason for the sales decline was a doctors’ strike in Spain. There was no sales growth in Germany, while sales in Italy increased significantly, albeit from a lower level than the other countries. Greece had little or no contribution. Germany has underperformed management's plans. Consequently, there will be a decrease in staff in regions where the market penetration is low. The company will instead focus on regions where it already has a foothold. In the conference call, the CEO mentioned that there is high competition for doctors’ time. Access from pharma companies is limited due to regulations. In particular, new bispecifics have captured most of doctors' time, leaving little room for commercial visits to discuss Pepaxti. The market potential remains the same, although it will likely take longer to reach it than previously estimated. However, costs will also be reduced. Based on the new information, we have revised our forecasts downwards. Our forecast was SEK28m in Q4 versus the actual SEK18.6m. We now estimate the company will make a loss for the whole year of 2027, although H2 will show positive results. We show our estimate changes below. In our estimates, assuming a deal for Pepaxti in Japan in 2026 which brings in an upfront, the company can achieve a positive result and positive cash flow with cash on hand of cSEK100m. We now expect the sales ramp-up over the next two years to be slower than previously estimated, but we have made more limited changes to our long-term forecast, assuming a similar long-term market penetration of Pepaxti. We mainly expect market penetration to be slower. We now forecast peak sales of SEK1.4bn, down from SEK1.6bn. This results in a new base case of SEK4.5 (SEK5.5). Our new bull case is SEK8 (SEK9) while we retain our previous bear case of SEK2. We will return with a full update after the Q4 report on February 19, when we might further revise our estimates slightly.
·4.2.My thoughts are that the price is 77% higher than the same time a year ago. We will probably have a similar development even with a possible New Share Issue in Q3, Historically it has gone up in connection with that. Yes, there is a disappointment about Q4 25 sales, but it is still a substantial sales increase from Q4 24, if one projects these facts, it could be a very strong Q3/Q4 this year. I am in no hurry, furthermore I believe that buying now under 3kr is a bargain.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
99 päivää sitten
‧35 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenThen surely all negative things should be priced in and clear by now and the price will probably land just under 2 at the report and then some talk and decision about an emission and then it's down to 1kr before the end of February. Like.
- ·6.2.Full-year sales for 2025 will amount to 71.2 MSEK, an increase of 125 percent compared to 2024. Are people reading the report or?6.2.6.2.Redeye 16.01: The main reason for the sales decline was a doctors’ strike in Spain. There was no sales growth in Germany, while sales in Italy increased significantly, albeit from a lower level than the other countries. Greece had little or no contribution. Germany has underperformed management's plans. Consequently, there will be a decrease in staff in regions where the market penetration is low. The company will instead focus on regions where it already has a foothold. In the conference call, the CEO mentioned that there is high competition for doctors’ time. Access from pharma companies is limited due to regulations. In particular, new bispecifics have captured most of doctors' time, leaving little room for commercial visits to discuss Pepaxti. The market potential remains the same, although it will likely take longer to reach it than previously estimated. However, costs will also be reduced. Based on the new information, we have revised our forecasts downwards. Our forecast was SEK28m in Q4 versus the actual SEK18.6m. We now estimate the company will make a loss for the whole year of 2027, although H2 will show positive results. We show our estimate changes below. In our estimates, assuming a deal for Pepaxti in Japan in 2026 which brings in an upfront, the company can achieve a positive result and positive cash flow with cash on hand of cSEK100m. We now expect the sales ramp-up over the next two years to be slower than previously estimated, but we have made more limited changes to our long-term forecast, assuming a similar long-term market penetration of Pepaxti. We mainly expect market penetration to be slower. We now forecast peak sales of SEK1.4bn, down from SEK1.6bn. This results in a new base case of SEK4.5 (SEK5.5). Our new bull case is SEK8 (SEK9) while we retain our previous bear case of SEK2. We will return with a full update after the Q4 report on February 19, when we might further revise our estimates slightly.
- ·4.2.My thoughts are that the price is 77% higher than the same time a year ago. We will probably have a similar development even with a possible New Share Issue in Q3, Historically it has gone up in connection with that. Yes, there is a disappointment about Q4 25 sales, but it is still a substantial sales increase from Q4 24, if one projects these facts, it could be a very strong Q3/Q4 this year. I am in no hurry, furthermore I believe that buying now under 3kr is a bargain.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
39 972
Myynti
Määrä
41 466
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 598 | - | - | ||
| 961 | - | - | ||
| 381 | - | - | ||
| 102 | - | - | ||
| 619 | - | - |
Ylin
2,845VWAP
Alin
2,7VaihtoMäärä
2,9 1 064 968
VWAP
Ylin
2,845Alin
2,7VaihtoMäärä
2,9 1 064 968
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 19.2. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 7.11.2024 |
2025 Q3 -tulosraportti
99 päivää sitten
‧35 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 19.2. | 7 päivää |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 | ||
2024 Q4 -tulosraportti 27.2.2025 | ||
2024 Q3 -tulosraportti 7.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 päivää sittenThen surely all negative things should be priced in and clear by now and the price will probably land just under 2 at the report and then some talk and decision about an emission and then it's down to 1kr before the end of February. Like.
- ·6.2.Full-year sales for 2025 will amount to 71.2 MSEK, an increase of 125 percent compared to 2024. Are people reading the report or?6.2.6.2.Redeye 16.01: The main reason for the sales decline was a doctors’ strike in Spain. There was no sales growth in Germany, while sales in Italy increased significantly, albeit from a lower level than the other countries. Greece had little or no contribution. Germany has underperformed management's plans. Consequently, there will be a decrease in staff in regions where the market penetration is low. The company will instead focus on regions where it already has a foothold. In the conference call, the CEO mentioned that there is high competition for doctors’ time. Access from pharma companies is limited due to regulations. In particular, new bispecifics have captured most of doctors' time, leaving little room for commercial visits to discuss Pepaxti. The market potential remains the same, although it will likely take longer to reach it than previously estimated. However, costs will also be reduced. Based on the new information, we have revised our forecasts downwards. Our forecast was SEK28m in Q4 versus the actual SEK18.6m. We now estimate the company will make a loss for the whole year of 2027, although H2 will show positive results. We show our estimate changes below. In our estimates, assuming a deal for Pepaxti in Japan in 2026 which brings in an upfront, the company can achieve a positive result and positive cash flow with cash on hand of cSEK100m. We now expect the sales ramp-up over the next two years to be slower than previously estimated, but we have made more limited changes to our long-term forecast, assuming a similar long-term market penetration of Pepaxti. We mainly expect market penetration to be slower. We now forecast peak sales of SEK1.4bn, down from SEK1.6bn. This results in a new base case of SEK4.5 (SEK5.5). Our new bull case is SEK8 (SEK9) while we retain our previous bear case of SEK2. We will return with a full update after the Q4 report on February 19, when we might further revise our estimates slightly.
- ·4.2.My thoughts are that the price is 77% higher than the same time a year ago. We will probably have a similar development even with a possible New Share Issue in Q3, Historically it has gone up in connection with that. Yes, there is a disappointment about Q4 25 sales, but it is still a substantial sales increase from Q4 24, if one projects these facts, it could be a very strong Q3/Q4 this year. I am in no hurry, furthermore I believe that buying now under 3kr is a bargain.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
39 972
Myynti
Määrä
41 466
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 598 | - | - | ||
| 961 | - | - | ||
| 381 | - | - | ||
| 102 | - | - | ||
| 619 | - | - |
Ylin
2,845VWAP
Alin
2,7VaihtoMäärä
2,9 1 064 968
VWAP
Ylin
2,845Alin
2,7VaihtoMäärä
2,9 1 064 968
Välittäjätilasto
Dataa ei löytynyt